Oral News and Research

RSS

Combination of infused vitamin C and conventional chemotherapy drugs stops ovarian cancer

Scientists at the University of Kansas Medical Center have determined that high doses of vitamin C, administered intravenously with traditional chemotherapy, helped kill cancer cells while reducing the toxic effects of chemotherapy for some cancer patients.

10 Feb 2014

e-Therapeutics initiates Phase I clinical trial with oral formulation of ETS2101 anti-cancer compound

e-Therapeutics plc (AIM:ETX) announced today that it has dosed the first healthy volunteer in a newly initiated Phase I clinical trial with an oral formulation of its anti-cancer compound, ETS2101.

10 Feb 2014

Ipsen’s phase III clinical trial evaluating Decapeptyl in patients with prostate cancer meets primary endpoints

Ipsen today announced that the phase III clinical trial evaluating Decapeptyl (triptorelin pamoate) 11.25 mg administered subcutaneously in patients with locally advanced or metastatic prostate cancer has met its primary endpoints.

10 Feb 2014

Henry Schein and ADA join forces to celebrate annual Give Kids A Smile Day

Henry Schein, Inc. (NASDAQ: HSIC), the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners, together with 26 of the Company's valued supplier partners, join the American Dental Association (ADA) today to celebrate the ADA's annual Give Kids A Smile Day.

9 Feb 2014

Study: Investigational drug effective in reducing mucormycosis infections

With very few treatment options available to fight deadly mucormycosis infections, a new Los Angeles Biomedical Research Institute (LA BioMed) study holds hope for adding to the arsenal of therapies physicians have to combat an increasingly common infection afflicting people with weakened immune systems.

7 Feb 2014

Incyte enters into clinical trial collaboration agreement with Merck to evaluate safety of IDO1 inhibitor

Incyte Corporation (Nasdaq: INCY) announced today that it has entered into a clinical trial collaboration agreement with Merck, through a Merck subsidiary, to evaluate the safety and efficacy of Incyte's oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360, and Merck's investigational anti-PD-1 immunotherapy, MK-3475, in a Phase I/II study in previously treated metastatic and recurrent non-small cell lung cancer (NSCLC), and other advanced or metastatic cancers.

5 Feb 2014

Viewpoints: Drop in abortion rates may have something to do with better contraception; GOP health law alternative 'designed to fail'

A new study released on Monday finds that the abortion rate among American women declined to its lowest level in more than three decades in 2011. ... Notably, though, the decline in abortions from 2008 to 2011 was mirrored by a decline in pregnancy rates that the researchers say may reflect stricter adherence to birth control methods during recession, and the growing use, especially among younger women, of reliable long-term contraceptives, like the intrauterine device, or IUD.

5 Feb 2014

Spinifex announces results of Phase 2 clinical trial of EMA401 in postherpetic neuralgia

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces that The Lancet has published the results of its Phase 2 clinical trial of its lead candidate, EMA401, in postherpetic neuralgia (PHN).

5 Feb 2014

Findings raise hope for new oral anticoagulants to treat patients with atrial fibrillation

Approximately one in two patients with atrial fibrillation (Afib) do not optimally reduce their risk of stroke or bleeding when treated with the most widely prescribed oral-anticoagulant therapy, according to a study published online in Circulation, the journal of the American Heart Association.

From Quest Diagnostics 5 Feb 2014

Complex intervention successful in reducing C-sections and neonatal morbities, say researchers

In a study to be presented on Feb. 6 in an oral plenary session at 8 a.m. CST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting-, in New Orleans, researchers will report that Cesarean deliveries reviews and best practices implementation are effective to provide optimal care by an appropriate management of medical interventions, leading to a significant reduction of cesarean deliveries and neonatal morbidity.

4 Feb 2014

Treating peanut allergy with oral immunotherapy changes DNA of immune cells

Treating a peanut allergy with oral immunotherapy changes the DNA of the patient's immune cells, according to a new study from the Stanford University School of Medicine and Lucile Packard Children's Hospital Stanford. The DNA change could serve as the basis for a simple blood test to monitor the long-term effectiveness of the allergy therapy.

31 Jan 2014

Key role for Fusobacterium adhesin in non-orthodontic periodontal inflammation

Researchers from China have found that patients with gingivitis and periodontitis are more likely to have Fusobacterium nucleatum carrying the novel Fusobacterium adhesin A than periodontally healthy people.

31 Jan 2014

Viewpoints: Obama drops 'grand bargain' talk; Mitch Mcconnell in tough spot on health law

What didn't make the cut? ... A "grand bargain": For three years, Obama pursued a big fiscal deal that would have traded higher taxes (a Democratic goal) for cuts in long-term spending on Medicare, Medicaid and Social Security (a Republican goal).

31 Jan 2014

Children with peanut allergies could benefit from oral immunotherapy treatment

Children and adolescents with peanut allergies could benefit from treatment with oral immunotherapy (OIT), in which peanut protein is consumed in increasingly larger amounts on a regular basis to build up tolerance, according to a phase 2 trial published in The Lancet.

31 Jan 2014

CTI announces initiation of pacritinib Phase 2 trial in AML patients with FLT3 mutations

Cell Therapeutics, Inc. today announced the initiation of an international cooperative group Phase 2 clinical trial of pacritinib in adult patients with relapsed acute myeloid leukemia (AML) with mutations of the FLT3 gene. Mutation of the FLT3 gene is found in approximately one-third of AML patients and is an independent risk factor for poor prognosis.

30 Jan 2014

Oramed Pharmaceuticals' ORMD-0801 Phase 2a study meets primary and secondary endpoints

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today results from its Phase 2a clinical trial for its ORMD-0801 oral insulin capsule for the treatment of type 2 diabetes. The trial was conducted under a United States Food and Drug Administration IND (Investigational New Drug) protocol. The Phase 2a study met all primary and secondary endpoints.

30 Jan 2014

Oral News and Research

Combination of infused vitamin C and conventional chemotherapy drugs stops ovarian cancer

e-Therapeutics initiates Phase I clinical trial with oral formulation of ETS2101 anti-cancer compound

Ipsen’s phase III clinical trial evaluating Decapeptyl in patients with prostate cancer meets primary endpoints

Henry Schein and ADA join forces to celebrate annual Give Kids A Smile Day

Study: Investigational drug effective in reducing mucormycosis infections

Incyte enters into clinical trial collaboration agreement with Merck to evaluate safety of IDO1 inhibitor

Viewpoints: Drop in abortion rates may have something to do with better contraception; GOP health law alternative 'designed to fail'

Spinifex announces results of Phase 2 clinical trial of EMA401 in postherpetic neuralgia

Findings raise hope for new oral anticoagulants to treat patients with atrial fibrillation

Complex intervention successful in reducing C-sections and neonatal morbities, say researchers

Treating peanut allergy with oral immunotherapy changes DNA of immune cells

Key role for Fusobacterium adhesin in non-orthodontic periodontal inflammation

Viewpoints: Obama drops 'grand bargain' talk; Mitch Mcconnell in tough spot on health law

Children with peanut allergies could benefit from oral immunotherapy treatment

CTI announces initiation of pacritinib Phase 2 trial in AML patients with FLT3 mutations

Oramed Pharmaceuticals' ORMD-0801 Phase 2a study meets primary and secondary endpoints

19 harmful chemicals in e-cigarettes

High doses of 4-MEI in carbonated beverages may result in higher incidence of leukemia, says study

Vaccine to treat precancerous cervical lesions triggers immune cell response

Altheus Therapeutics receives patent for oral combination therapy for treating inflammatory bowel disease

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News